Human ANTI-B7RP1 Neutralizing Antibodies
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 60/700,265, filed Jul 18, 2005. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,072,090 | Human Anti-B7RP1 Neutralizing Antibodies In force · High confidence | Amgen Inc. | In force | High confidence | ||
| US 7,868,140 | Human ANTI-B7RP1 Neutralizing Antibodies In force · High confidence | E. R. Squibb & Sons, L.L.C. | In force | High confidence | ||
| US 8,981,071 | Human anti-B7RP1 Neutralizing Antibodies In force · High confidence | E. R. Squibb & Sons, L.L.C. | In force | High confidence | ||
| US 9,266,945 | Human Anti-B7RP1 Neutralizing Antibodies Term ended Ended no later than Jul 18, 2026 · Medium confidence | E. R. Squibb & Sons, L.L.C. | Term ended | Ended no later than Jul 18, 2026 | Medium confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by E R Squibb and Sons LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.